Findings on Health Economics and Policy Reported by Researchers at French National Institute of Health and Medical Research (INSERM) (A Payer Perspective of the Hospital Inpatient Additional Care Costs of Antimicrobial Resistance in France: A …)

2019 JUN 07 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Data detailed on Health Economics and Policy have been presented. According to news reporting from Montigny-le-Bretonneux, France, by NewsRx journalists, research stated, “Antimicrobial resistance (AMR) has become one of the biggest threats to global public health given its association with mortality, morbidity and cost of health care. However, little is known on the economic burden of hospitalization attributable to AMR from a public health insurance perspective.”

The news correspondents obtained a quote from the research from the French National Institute of Health and Medical Research (INSERM), “We assessed the excess costs to the French public health insurance system attributable to AMR infections in hospitals. Bacterial infectious disease-related hospitalizations were extracted from the National health data information system for all stays occurring in 2015. Bacterial infections, strains, and microbial resistance were identified by specific French ICD-10 codes. Information about health care expenditure, co-morbidities and demographic characteristics (i.e. gender, age) are provided. We used a matched case-control approach to determine the excess of reimbursements paid to stays with AMR compared to stays with an infection without resistance. Cases and controls were matched on gender, age, Charlson comorbidity index, category of infection, infection as principal diagnosis (two classes), microorganism and hospital status. The overall AMR cost was extrapolated to stays with AMR and excluded from the sample (multiple infections), and a second extrapolation was performed to consider stays with unknown resistance status. The final sample included 52,921 matched-pairs (98.2% cases). Our results suggest that AMR overall cost reached EUR109.3 million in France with a mean of EUR1103 per stay; extrapolation to the entire database shows that the overall cost could potentially reach EUR287.1 million if all cases would be identified. The mean excess length of hospital stay attributable to AMR was estimated at 1.6 days. AMR causes substantial cost burden in France for the public health insurance.”

According to the news reporters, the research concluded: “Our study confirms the need to reinforce programs to prevent AMR infection and thereby reduce their economic burden.”

For more information on this research see: A Payer Perspective of the Hospital Inpatient Additional Care Costs of Antimicrobial Resistance in France: A Matched Case-Control Study. Applied Health Economics and Health Policy, 2019;17(3):381-389. Applied Health Economics and Health Policy can be contacted at: Adis International LTD, 41 Centorian Dr, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.

Our news journalists report that additional information may be obtained by contacting L. Watier, Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Inserm, UVSQ, Institut Pasteur, Paris-Saclay University, 2, avenue de la Source de la Bievre, 78180, Montigny-Le-Bretonneux, France, . Additional authors for this research include M. Opatowski, C. Brun-Buisson, K. Cosker, D. Guillemot, J. Salomon, P. Tuppin, G. de Lagasnerie and L. Watier.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/s40258-018-0451-1. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the journal Applied Health Economics and Health Policy is: Adis International LTD, 41 Centorian Dr, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.

(Our reports deliver fact-based news of research and discoveries from around the world.)